{"url":"https://lda.senate.gov/api/v1/filings/30464bb2-d64f-46f8-8908-d88a8342a856/","filing_uuid":"30464bb2-d64f-46f8-8908-d88a8342a856","filing_type":"RR","filing_type_display":"Registration","filing_year":2025,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/30464bb2-d64f-46f8-8908-d88a8342a856/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Rachel Sher","dt_posted":"2025-04-14T11:46:52-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1050 Connecticut Ave NW","registrant_address_2":"Suite 600","registrant_different_address":null,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":23645,"url":"https://lda.senate.gov/api/v1/registrants/23645/","house_registrant_id":30207,"name":"MANATT, PHELPS, AND PHILLIPS","description":"Law firm","address_1":"1700 M St NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20036","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JUNE DEHART","contact_telephone":"+1 202-585-6500","dt_updated":"2026-07-31T09:29:47.059086-04:00"},"client":{"id":65725,"url":"https://lda.senate.gov/api/v1/clients/65725/","client_id":65725,"name":"DENALI THERAPEUTICS","general_description":"Biopharmaceutical Company","client_government_entity":null,"client_self_select":false,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-01-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Rare Pediatric Disease Priority Review Voucher (PRV) Program Reauthorization; Medicaid policies that impact access to innovative treatments for pediatric rare diseases; rare disease drug development","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":148266,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"SHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":146347,"prefix":null,"prefix_display":null,"first_name":"HEIDE","nickname":null,"middle_name":null,"last_name":"BAJNRAUH","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":148143,"prefix":"mrs","prefix_display":"MRS.","first_name":"KENDALL","nickname":null,"middle_name":"BYRUM","last_name":"HUSSEY","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}